. 2018 Mar 13;16:62. doi: 10.1186/s12967-018-1440-8

Table 1.

Characteristics of the patients with de novo immune hepatitis and chronic rejection

Patient	Gender	Original disease	Baseline IS	Biopsy date (biopsy #)	Months after LT	Diagnosis
1	F	Drug toxicity	CYA, AZA, ST	18-02-00^a	21	dnIH
2	M	Alcoholic cirrhosis	CYA(N), MMF, ST	15-03-04^a	58	dnIH
3	M	HCV + alcoholic cirrhosis	CYA(N), ST, anti-CD25	13-07-04 (B1)^a 05-09-04 (B2)	32 34	dnIH
4	F	Alcoholic cirrhosis	CYA, MMF, ST	16-07-04 (B1)^a 13-06-05 (B2)	10 21	dnIH
5	F	Unknown	CYA, MMF, ST	28-01-10^a	32	dnIH
6	F	PBC	CYA, MMF, ST	19-04-10^a	13	dnIH
7	F	HCV cirrhosis	CYA, MMF, ST	30-07-12 (B1) 05-12-12 (B2)^a	3 8	HCV + AR dnIH
8	M	HCV cirrhosis	TAC, ST	28-12-00^a	14	dnIH
9	F	HCV cirrhosis	CYA, MMF, ST	18-06-09^a	57	dnIH
10	F	SBC	CYA (N), MMF, ST	19-02-14^a	87	dnIH
11	F	HCV cirrhosis	CYA, AZA, ST	25-04-97^a	7	dnIH
12	F	HCV cirrhosis	CYA(N), ST, anti-CD25	04-02-02^a	19	dnIH
CR-1	F	HCV cirrhosis	TAC, MMF, ST	09-11-04	29	CR
CR-2	F	PBC	Sotrastaurin	01-11-11	12	Early CR
CR-3	M	Caroli disease	TAC, MMF, ST	08-03-13	17	CR
CR-4	M	Alcoholic cirrhosis + NASH	TAC, MMF, ST, anti-CD25	30-07-13	6	Early CR
CR-5	M	HCV cirrhosis + HC	CYA, MMF, ST	07-06-13	11	CR
CR-6	M	Cryptogenic	TAC, MMF, ST	08-03-12	9	Early CR
CR-7	M	Re-transplant	TAC, MMF, ST	05-08-10	74	CR
CR-8	M	Alcoholic cirrhosis	TAC, anti-CD25	12-03-14	84	CR
CR-9	M	PBC	TAC, anti-CD25	22-01-07	75	CR

M, male; F, female; LT, liver transplant; HCV, hepatitis C virus; PBC, primary biliary cirrhosis; SBC, secondary biliary cirrhosis; IS, immunosuppression; TAC, tacrolimus; AR, acute rejection; CYA, cyclosporine; N, Neoral; MMF, mofetil mycophenolate; ST, steroids; AZA, azathioprine; dnIH, de novo immune hepatitis; CR, chronic rejection; NASH, non-alcoholic steatohepatitis; HC, hepatocellular carcinoma

^adnIH diagnostic biopsy